HomeAuthorNatasha Svast - Verséa

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/09/2202092_Versea-Easy-Lab-24ct-Half-Sidekick-Counter-Display.png?resize=844%2C640&ssl=1

At this year’s NACS Show 2022 Verséa Holdings, Inc. is launching their new business division Verséa Health and their Product Line Portfolio Verséa Easy Lab™. James Olin, Chief Commercial Officer at Verséa, explains the reason behind the launch: “Verséa Health was created with a mission to give millions of Americans direct-access to the most essential...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/09/Verséa-Ophthalmics-Diagnostic-Platform_Page_1.jpg?resize=1190%2C640&ssl=1

New innovative, rapid, tear-based, POC diagnostic test platform is designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders   At this year’s Expo of the American Academy of Ophthalmology AAO 2022 – booth # 1251, Verséa Ophthalmics is launching their comprehensive Product Portfolio and demonstrating...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/09/USF-Fair.jpg?resize=847%2C640&ssl=1

Verséa is looking for this year’s brightest students and recent graduates to join our Paid Internship Program! Today we are at the University of Tampa searching for ambitious individuals who wish to gain professional experience in Marketing & Business Development at one of the fastest-growing healthcare companies in the U.S. CONTACT US TODAY at 1.813.345.2185...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/09/outlined-blue-eye.jpg?resize=960%2C350&ssl=1

“With exclusive global licensing rights to AXIM’s Eye Diagnostics portfolio, Verséa will be introducing a new innovative, rapid, tear-based, POC lab-testing platform designed specifically to assist eye-care clinicians in detecting and quantifying a variety of biomarkers associated with external ocular disorders.”   Verséa Ophthalmics, LLC, a business division of Verséa Holdings, Inc. (“Verséa”), signed exclusive...

https://i0.wp.com/www.versea.com/wp-content/uploads/2021/03/Sean-Fetcho4.png?resize=500%2C640&ssl=1

Sean Fetcho, the co-founder and CEO of Verséa Holdings, Inc. (“Verséa”) has been announced as a Tampa Bay Business Journal 40 under 40 honoree. This is the most competitive award given by the Tampa Bay Business Journal, with over 500 nominations this year alone. The award recognizes exceptional business professionals, leaders and innovators under the...

https://i0.wp.com/www.versea.com/wp-content/uploads/2022/08/versea-occular-eye-technology-blue-3x1-1-e1661466967859.jpg?resize=711%2C399&ssl=1

Verséa Holdings, Inc. (“Verséa”) welcomes Rob Sambursky, MD, who joined the company as the President, effective as of August 5, 2022. Dr. Sambursky will support corporate strategy and operations as well as lead the company’s expansion into the ophthalmic market. Verséa recently launched a new business division, Verséa Ophthalmics, with a goal of providing innovative...

https://i0.wp.com/www.versea.com/wp-content/uploads/2021/03/women-in-science-l.jpg?resize=1200%2C640&ssl=1

Verséa Discovery successfully ran its first validation test assays at the UCSD Biomedical Lab using its proprietary VCX™ Discovery Platform   The cellular based platform VCX™ Discovery Platform follows a proprietary process developed by Verséa Discovery. Through machine learning, the system links highly specific cellular functions (focused on mitochondrial biology and second messenger signaling) to...